Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stockwatch: Competing for attention

This article was originally published in Scrip

Executive Summary

This has been a week of dull news and JPMorgan is to blame. The Scrip electronic post-bag has been overflowing with press releases on Interim Management Statements, reviews of recent achievements, and minor service deals dressed up as strategically significant developments. In short, a lot of companies have been fairly desperate to find something new to say to the media to decorate their appearance at the year’s first and – some would argue – most important investment conference of the year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC015879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel